Jonathan Leff
Director/Board Member chez Avalyn Pharma, Inc.
Profil
Jonathan Leff has over 25 years of clinical development experience in the biotechnology and pharmaceutical industry he focuses on providing his strategic drug development expertise to aid companies from target identification to the market.
He is currently a member of the board of directors for NorthSea.
Prior to joining Sofinnova in 2020, Jonathan served as Senior Vice President and Chief Medical Officer of Ascendis Pharma, a biotechnology company developing medicines for rare endocrine disorders.
Previously Dr. Leff served as Executive Vice President, Research and Development at InterMune (acquired by Roche/Genentech in 2014) where he oversaw the development and US approval of Esbriet® (oral pirfenidone) for the treatment of idiopathic pulmonary fibrosis.
Before InterMune, he was Chief Medical Officer at KaloBios Pharmaceuticals, and Vice President and Chief Medical Officer at Halozyme Therapeutics.
Additionally, Dr. Leff held various positions at Roche, Amgen, and Merck.
Jonathan earned a B.A.
in Chemistry from the University of Pennsylvania and received his M.D.
from the University of Pennsylvania School of Medicine.
He completed his medical training in Internal Medicine and Pulmonary and Critical Care Medicine at the University of Colorado, Denver.
Postes actifs de Jonathan Leff
| Sociétés | Poste | Début |
|---|---|---|
Avalyn Pharma, Inc.
 Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Director/Board Member | 01/04/2017 |
Sofinnova Investments, Inc.
 Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Private Equity Investor | 17/03/2020 |
NorthSea Therapeutics BV
 NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Director/Board Member | 01/02/2022 |
Anciens postes connus de Jonathan Leff
| Sociétés | Poste | Fin |
|---|---|---|
| AEROVATE THERAPEUTICS, INC. | Director/Board Member | 01/04/2021 |
| ASCENDIS PHARMA A/S | Chief Tech/Sci/R&D Officer | 01/10/2019 |
| INTERMUNE INC | Chief Tech/Sci/R&D Officer | 31/03/2015 |
| HUMANIGEN, INC. | Sales & Marketing | 01/02/2012 |
| HUMANIGEN, INC. | Corporate Officer/Principal | 01/02/2012 |
Formation de Jonathan Leff
| University of Pennsylvania | Undergraduate Degree |
| Perelman School of Medicine | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 5 |
|---|---|
| AMGEN INC. | Health Technology |
| HALOZYME THERAPEUTICS, INC. | Health Technology |
| HUMANIGEN, INC. | Health Technology |
| ASCENDIS PHARMA A/S | Health Technology |
| AEROVATE THERAPEUTICS, INC. | Health Technology |
| Entreprise privées | 6 |
|---|---|
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Avalyn Pharma, Inc.
Avalyn Pharma, Inc. Pharmaceuticals: MajorHealth Technology Avalyn Pharma, Inc. manufactures pharmaceutical products. It develops improved therapies for the treatment of idiopathic pulmonary fibrosis (IPF) and other severe respiratory diseases. The company was founded by Richard Glenn Vincent and Mark W. Surber in 2011 and is headquartered in Seattle, WA. | Health Technology |
Sofinnova Investments, Inc.
Sofinnova Investments, Inc. Investment ManagersFinance Sofinnova Investment Inc (Sofinnova Investment) is a venture capital firm founded in 1976 by Jacques F. vallle & Joel F. Martin. The firm is headquartered in Menlo Park, California. | Finance |
Hoffmann-La Roche, Inc.
 Hoffmann-La Roche, Inc. BiotechnologyHealth Technology Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ. | Health Technology |
Roche Palo Alto LLC
 Roche Palo Alto LLC Pharmaceuticals: MajorHealth Technology Roche Palo Alto LLC discovers and develops medicines. Its medicines are used for the treatment of central nervous system, inflammation, metabolism, oncology, and virology diseases. The company was founded in 1961 and is headquartered in Palo Alto, CA. | Health Technology |
NorthSea Therapeutics BV
NorthSea Therapeutics BV BiotechnologyHealth Technology NorthSea Therapeutics BV operates as a biotechnology company. It develops oral, structurally engineered fatty acid therapeutics. The company was founded by Hilde H. Steineger and David A. Fraser and is headquartered in Naarden, the Netherlands. | Health Technology |
